



(51) International Patent Classification:

A61K 9/00 (2006.01) A61P 37/02 (2006.01)
A61P 17/00 (2006.01) A61P 37/06 (2006.01)
A61P 29/00 (2006.01) C07K 16/28 (2006.01)
A61P 37/00 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2021/061764

(22) International Filing Date:

03 December 2021 (03.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/121,194 03 December 2020 (03.12.2020) US

(71) Applicant: **BIOGEN MA INC.** [US/US]; 225 Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **GAUDREAU, Francois**; 225 Binney Street, Cambridge, Massachusetts 02142 (US). **NAIK, Himanshu**; 225 Binney Street, Cambridge, Massachusetts 02142 (US).

(74) Agent: **BRENNAN, Jack et al.**; Fish & Richardson, P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):


ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: METHODS OF TREATING CUTANEOUS LUPUS ERYTHEMATOSUS AND SYSTEMIC LUPUS ERYTHEMATOSUS

FIGURE 1



(57) Abstract: Dosage regimens of anti-Blood Dendritic Cell Antigen 2 antibodies are provided for use in the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))